Tenax Therapeutics, Inc.
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)

Last updated:

Abstract:

This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

Status:
Application
Type:

Utility

Filling date:

15 Dec 2020

Issue date:

17 Jun 2021